Im2pact Consortium company summary
Im2pact Consortium is a company in the Biotechnology Research industry, founded in 2019. On LinkedIn the company has around 51 employees.
What technology does Im2pact Consortium use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Im2pact Consortium
A new consortium of 27 international partners from academia, industry, and small and medium enterprises, aims to tackle the unmet challenge of discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative and metabolic diseases. The blood-brain barrier (BBB) is a protective layer between the brain’s blood vessels and the cells that make up brain tissue. This barrier provides a defence against the pathogens and toxins that may be in our blood, allowing very few molecules to pass through. It can also prevent many drugs from passing through into the brain, and this presents a major problem in treating neurological conditions and metabolic diseases, especially when using antibody therapies.On the other hand, several neurological diseases could originate from a dysfunctional blood brain barrier.
Compare companies similar to Im2pact Consortium
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Im2pact Consortium im2pact.org | Biotechnology Research | 51 | 2019 | - |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Im2pact Consortium
What does Im2pact Consortium do?
A new consortium of 27 international partners from academia, industry, and small and medium enterprises, aims to tackle the unmet challenge of discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative and metabolic diseases. The blood-brain barrier (BBB) is a protective layer between the brain’s blood vessels and the cells that make up brain tissue. This barrier provides a defence against the pathogens and toxins that may be in our blood, allowing very few molecules to pass through. It can also prevent many drugs from passing through into the brain, and this presents a major problem in treating neurological conditions and metabolic diseases, especially when using antibody therapies.On the other hand, several neurological diseases could originate from a dysfunctional blood brain barrier.
How many employees does Im2pact Consortium have?
Im2pact Consortium has around 51 employees on LinkedIn.
When was Im2pact Consortium founded?
Im2pact Consortium was founded in 2019.
Build a lead list from companies like Im2pact Consortium
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.